News

30th October 2017

ECTRIMS-ACTRIMS: Phase III data EXPAND on siponimod for secondary progressive multiple sclerosis

https://www.brainwork.md/content/uploads/2017/10/MPR426-Brainwork-illustrations-articles-V00-02-20171027_brain.png 898 506 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 30th October 2017 13th July 2018

Data presented at the recent 7th joint ECTRIMS-ACTRIMS meeting in Paris delved deeper into the efficacy of siponimod in the treatment of secondary progressive MS (SPMS). As Robert Fox (Mellen…

Peter Stevenson, PhD
0
0

27th October 2017

Welcome to Brainwork

https://www.brainwork.md/content/uploads/2017/10/MPR426-Brainwork-illustrations-articles-V00-02-20171027_neurons.png 899 506 Prof. Dr. Krassen Nedeltchev Prof. Dr. Krassen Nedeltchev https://secure.gravatar.com/avatar/aaadc696c1b66fe476051e7e4012d01a?s=96&d=mm&r=g 27th October 2017 27th October 2017

Dear colleagues, Thank you for subscribing to BRAINWORK! Your participation has made our eLearning initiative stronger and more wide-ranging! What is Brainwork? Brainwork is a new online platform that aims…

Prof. Dr. Krassen Nedeltchev
3
7

27th October 2017

ECTRIMS-ACTRIMS: OBOE study explores biomarkers of neurodegeneration and inflammation in multiple sclerosis

https://www.brainwork.md/content/uploads/2017/10/welcome-to-brainwork-ectrims-2017.jpg 1920 1080 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 27th October 2017 13th July 2018

The development and characterisation of biomarkers in multiple sclerosis (MS) could be a crucial step in understanding disease pathways, as well as the therapeutic mechanisms of disease-modifying treatments. So was…

Peter Stevenson, PhD
0
0

Brainwork-DiabeticDrugMayBenefitHigh-RiskStrokePatients

25th October 2017

Diabetes drug may benefit high-risk stroke patients

https://www.brainwork.md/content/uploads/2017/10/Brainwork-DiabeticDrugMayBenefitHigh-RiskStrokePatients.jpg 4064 2710 Camilla Norrmén, PhD Camilla Norrmén, PhD https://secure.gravatar.com/avatar/c5fc8d4c102d9ee8db3f93d7f9c6ecd2?s=96&d=mm&r=g 25th October 2017 13th July 2018

A study showed last year that the insulin-sensitizing drug pioglitazone reduces the risk for stroke in patients with recent ischemic strokes. A new secondary analysis of the trial results found…

Camilla Norrmén, PhD
0
0

24th October 2017

NAVIGATE ESUS: Rivaroxaban vs aspirin study terminated due to comparable efficacy

https://www.brainwork.md/content/uploads/2017/10/Brainwork-NavigateESUS.jpg 2992 2000 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th October 2017 13th July 2018

Early discontinuation has been announced for the Phase III NAVIGATE ESUS study – led by Bayer AG and its development partner Janssen Research & Development, LLC – which had been…

Peter Stevenson, PhD
0
0

ECTRIMS-ACTRIMS: Phase III data EXPAND on siponimod for secondary progressive multiple sclerosis

Welcome to Brainwork

ECTRIMS-ACTRIMS: OBOE study explores biomarkers of neurodegeneration and inflammation in multiple sclerosis

​Diabetes drug may benefit high-risk stroke patients

​NAVIGATE ESUS: Rivaroxaban vs aspirin study terminated due to comparable efficacy

Diabetes drug may benefit high-risk stroke patients

NAVIGATE ESUS: Rivaroxaban vs aspirin study terminated due to comparable efficacy